Login or sign up
For business

Phathom pharmaceuticals

3.9ยท 10 reviews
Average ratingAverage
3.9/ 5

Based on 10 reviews

530%
430%
340%
20%
10%
Ask AI

Ask Trustburn about Phathom pharmaceuticals

Based on 10 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website โ€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Phathom pharmaceuticals

A late clinical-stage biopharmaceutical company committed to transforming the treatment landscape for people suffering from GI diseases related to acid.

Phathom Pharmaceuticals: Revolutionizing the Treatment of GI Diseases Related to Acid

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company that is dedicated to transforming the treatment landscape for people suffering from gastrointestinal (GI) diseases related to acid. The company was founded in 2017 and has since been working tirelessly towards developing innovative therapies that can help patients with unmet medical needs.

The team at Phathom Pharmaceuticals comprises experienced professionals who are passionate about improving patient outcomes. They have a deep understanding of the underlying mechanisms of acid-related GI diseases and are committed to developing safe and effective treatments that can address these conditions.

One of the key areas of focus for Phathom Pharmaceuticals is gastroesophageal reflux disease (GERD), which affects millions of people worldwide. GERD occurs when stomach acid flows back into the esophagus, causing symptoms such as heartburn, regurgitation, and difficulty swallowing. While there are several treatments available for GERD, many patients continue to experience symptoms despite taking medication.

Phathom Pharmaceuticals has developed a novel therapy called vonoprazan, which works by inhibiting gastric acid secretion through a different mechanism than currently available therapies. Vonoprazan has shown promising results in clinical trials and could potentially provide relief for patients with refractory GERD who have not responded well to other treatments.

In addition to GERD, Phathom Pharmaceuticals is also focused on developing therapies for other acid-related GI diseases such as erosive esophagitis (EE) and Zollinger-Ellison syndrome (ZES). EE is a condition where stomach acid damages the lining of the esophagus, while ZES is a rare disorder where tumors in the pancreas or duodenum cause excessive production of gastric acid.

Phathom's pipeline includes two additional product candidates: PHAT-629 - an investigational compound designed as an adjunctive treatment with proton pump inhibitors (PPIs) in patients with EE; PHAT-210 - an investigational compound designed as an adjunctive treatment with PPIs in patients with ZES or other hypersecretory conditions associated with elevated levels of gastrin.

The company's commitment towards innovation extends beyond its product pipeline. Phathom Pharmaceuticals has also developed proprietary technology platforms that enable efficient drug discovery and development processes. These platforms leverage cutting-edge techniques such as computational modeling, high-throughput screening, and medicinal chemistry optimization to accelerate drug development timelines while maintaining high standards for safety and efficacy.

In conclusion, Phathom Pharmaceuticals represents a beacon of hope for millions suffering from GI diseases related to acid. With its innovative therapies backed by robust scientific research and state-of-the-art technology platforms, this late clinical-stage biopharmaceutical company is poised to revolutionize how we treat these debilitating conditions. As they continue their journey towards bringing new treatments forward into commercialization it will be exciting watching them grow!

Address
100 campus drive
Categories
Biotechnology